Viewing Gene With Clinical Trials Data

Home Icon Home Search Icon Search Alerts Icon Stocks Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs eRecord Icon eRecord
Report Bug Request Feature
Gene Data From HGNC: https://www.genenames.org/download/statistics-and-files/
Symbol: BRCA1
Name: BRCA1 DNA repair associated
Location: 17q21.31
Locus Group: protein-coding gene
Gene Type: Protein Coding
Locus Type: gene with protein product
ID+ Clinical Trials CompTox DrugMatrix Conditions Design Enrollment Locations Outcomes
Clinical Trials Data: https://classic.clinicaltrials.gov/api/gui/ref/download_all

Clinical Studies

NCT Number Status Brief Title View
NCT00001468 Outcomes of Education and Counseling for BRCA1 Testing View
NCT00006421 Breast Imaging Studies in Women at High Genetic Risk of Breast Cancer Annual Follow-Up Study View
NCT00043472 Removal of the OvariesFallopian Tubes and CA-125 Screening to Reduce the Risk of Ovarian Cancer in Women at Increased Genetic Risk View
NCT00155896 Establishing the Incidences of BRCA1 and BRCA2 Mutation by Combining DHPLC and Direct Sequencing in Ovarian Cancer View
NCT04190667 Homologous Recombination Deficiency Status in Epithelial Ovarian Cancer View
NCT00256217 Chemoprevention Trial - Anastrozole in Ductal Carcinoma In Situ DCIS in Postmenopausal Women View
NCT00509509 High Risk Breast Cancer Screening Program View
NCT00783822 Effects of Rapid Genetic Counseling and Testing in Newly Diagnosed Breast Cancer Patients View
NCT00858078 A Qualitative Exploration of the Impact of Positive BRCA12 Mutation Status on the Lives of Young Women View
NCT03162276 Trial of Inquiry Based Stress Reduction IBSR Program for BRCA12 Mutation Carriers View
NCT01206218 Evaluation of Customized Treatment According to BRCA1 Assessment in Patients With Advanced Gastric Cancer View
NCT01367639 Trial of Inquiry Based Stress Reduction IBSR Program for BRCA12 Mutation Carriers View
NCT01409226 30 Tesla Magnetic Resonance Imaging for Breast Cancer Detection in High Risk Women View
NCT01630226 Cisplatin-monotherapy in the Treatment of BRCA1 Positive Breast Cancer Patients in Poland View
NCT00006425 Breast Imaging Studies in Women at High Genetic Risk of Breast Cancer Menstrual Cycle Study View
NCT03358004 the Role of Two Different Metronomic Chemotherapy Regimens in Locally Advanced or Metastatic Triple Negative Breast Cancer Patients TNBC as Maintenance Therapy After First Line Treatment View
NCT02826512 A Feasibility Study of Niraparib for Advanced BRCA1-like HER2-negative Breast Cancer Patients View
NCT04251052 A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer View
NCT02526719 Nipple Delay Prior to Nipple Sparing Mastectomy A Pilot RCT View
NCT04122625 Study to Assess Safety and Efficacy of the Second Mitochondrial-derived Activator of Caspases SMAC Mimetic Debio 1143 View
NCT02203513 A Phase II Single Arm Pilot Study of the Chk12 Inhibitor LY2606368 in BRCA12 Mutation Associated Breast or Ovarian Cancer Triple Negative Breast Cancer High Grade Serous Ovarian Cancer and Metastatic Castrate-Resistant Prostate Cancer View
NCT03570125 BRCA Main Home Nutritional Intervention-random Study View
NCT04683068 Promoting Mens Adherence to BRCA12 Germline Genetic Testing View
NCT04261465 NUVOLA TRIAL Open-label Multicentre Study View
NCT01560663 Predictors of Response to Neoadjuvant Docetaxel-Carboplatin Chemotherapy for Patients With Stage II and III Triple Negative Breast Cancer View
NCT04712890 Determination of Prevalence and Features of HRRm mCRPC ADAM View
NCT05327010 Testing the Combination of the Anti-cancer Drugs ZEN003694 ZEN-3694 and Talazoparib in Patients With Advanced Solid Tumors The ComBET Trial View
NCT05334836 Determination of Pancreatic Steatosis Prevalence and Correlation With High-risk Cyst Features View
NCT06033092 Low Dose TamOxifen and LifestylE Changes for bReast cANcer prevenTion View
NCT03040791 Nivolumab in Prostate Cancer With DNA Repair Defects ImmunoProst Trial View
NCT01672671 BRCA1-associated DNA Repair Dysfunction in Patients With Early Triple Negative Breast Cancer Treated With Neoadjuvant Platinum-based Chemotherapy View
NCT04431024 Prospective Evaluation of High Resolution Dual Energy Computed Tomographic Imaging Noninvasive Liquid Biopsies and Minimally Invasive Surgical Surveillance for Early Detection of Mesotheliomas in Patients With BAP1 Tumor Predisposition Syndrome View
NCT00416754 Genetic Counseling in Women at Risk for BRCA1 or BRCA2 Mutations View
NCT00413491 National Screening in Denmark With MR Versus Mammography and Ultrasound of Women With BRCA1 or BRCA2 Mutations View
NCT04367675 INO 5401 Vaccination in BRCA12 Mutation Carriers View
NCT01251900 BRCA Mutations in Latinas View
NCT00494442 Study to Assess the Efficacy and Safety of a PARP Inhibitor for the Treatment of BRCA-positive Advanced Ovarian Cancer View
NCT02810743 Substantially Improving the Cure Rate of High-risk BRCA1-like Breast Cancer View
NCT00165152 Counseling Interventions for BRCA 12 Cancer Susceptibility Testing View
NCT01339650 Study of ABT-767 in Subjects With Breast Cancer 1 and Breast Cancer 2 BRCA 1 and BRCA 2 Mutations and Solid Tumors or High Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer View
NCT01346761 Risk Education and Assessment for Cancer Heredity View
NCT01374685 Family Communication of Hereditary Breast and Ovarian Cancer Risk Among African Americans View
NCT01386411 Understanding Decision Making Processes for Undergoing Genetic Testing Among Women With Newly Diagnosed Breast Cancer View
NCT04425200 Prevalence of HRR-related Genes Mutations and Prognosis in Metastatic Castration Resistant Prostate Cancer mCRPC Patients in Real World Setting View
NCT01990352 Correlate BRCA1 Protein Expression With Response to DNA Damaging Chemotherapy View
NCT01990521 Prostate Screening Study Using MRI in BRCA Carriers View
NCT00419510 Genetic Counseling in African American Women View
NCT04439227 Testing AZD1775 as a Potential Targeted Treatment in Cancers With BRCA Genetic Changes MATCH-Subprotocol Z1I View
NCT01907438 Transformation Potential of E2 Exposed Breast Cancer Susceptibility Gene Mutation Heterozygous Epithelial Breast Cells View
NCT01445418 AZD2281 Plus Carboplatin to Treat Breast and Ovarian Cancer View
NCT00478699 Randomized Customized Adjuvant Chemotherapy GECP-SCAT View
NCT01482715 A Study of Oral Rucaparib in Patients With a Solid Tumor Phase I or With gBRCA Mutation Ovarian Cancer Phase II View
NCT02000089 The Cancer of the Pancreas Screening-5 CAPS5Study View
NCT00588263 Anonymous Testing of Pathology Specimens for BRCA Mutations in Ashkenazi Jewish Individuals Who Have Cancer View
NCT00597987 BRCA1 Haploinsufficiency and Gene Expression View
NCT00617656 Study to Evaluate Treatment Customized According to RAP80 and BRCA1 in Patients With Advanced Lung Carcinoma View
NCT00628251 Dose-finding Study Comparing Efficacy and Safety of a PARP Inhibitor Against Doxil in BRCAve Advanced Ovarian Cancer View
NCT00685256 Standard Genetic Counseling With or Without a Decision Guide in Improving Communication Between Mothers Undergoing BRCA12 Testing and Their Minor-Age Children View
NCT04548752 Testing the Addition of Pembrolizumab an Immunotherapy Cancer Drug to Olaparib Alone as Therapy for Patients With Pancreatic Cancer That Has Spread With Inherited BRCA Mutations View
NCT01608074 Radical Fimbriectomy for Young BRCA Mutation Carriers View
NCT00782574 Phase I AZD2281Cisplatin in Advanced Solid Tumour Patients View
NCT01611727 Open-LabelNon-Randomized Trial of Cisplatin Chemotherapy in BRCA1-Positive Metastatic Breast Cancer Patients View
NCT00823654 Serum Biomarkers to Characterize the Effects of Therapy on Ovarian Reserve in Premenopausal Women With Early-stage Breast Cancer or BRCA Mutations View
NCT00855998 Thymidine Kinase 1 in Risk Assessment for Hereditary Breast Ovarian Cancer View
NCT00883480 Individualized Treatment Based on Epidermal Growth Factor Receptor Mutations and Level of BRCA1 Expression in Advanced Adenocarcinoma View
NCT00897455 Studying Breast Cancer Risk in Women Who Are BRCA1BRCA2 Mutation Carriers View
NCT04613440 FaCT Trial Facilitated Cascade Testing Trial View
NCT01661868 Olaparib for Patients With Recurrent BRCA Deficient Ovarian Cancer View
NCT01670500 Cisplatin vs DoxorubicinCyclophosphamide in BrCa View
NCT00986206 Lysophosphatidic Acid Assay in Patients With Ovarian Cancer or Who Are at Risk for Ovarian Cancer View
NCT01078662 Open Label Study to Assess Efficacy and Safety of Olaparib in Confirmed Genetic BRCA1 or BRCA2 Mutation Pats View
NCT01088906 Study of Pemetrexed Plus Cisplatin as First-line Therapy in Patients With Advanced Non-squamous NSCLC View
NCT01097278 S0812 High Dose Cholecalciferol in Premenopausal Women at High-Risk for Breast Cancer View
NCT01102569 Pancreatic Cancer Genetics View
NCT04711109 Studying the Effect of Denosumab on Preventing Breast Cancer in Women With a BRCA1 Germline Mutation View
NCT02154633 Lessons Learned From the Family Gene Toolkit View
NCT01276769 Comparison Study of Neoadjuvant Paclitaxel Plus CarboplatinEpirubicin Treatment in Triple-negative Breast Cancer View
NCT01286987 Study of Talazoparib a PARP Inhibitor in Patients With Advanced or Recurrent Solid Tumors View
NCT00494234 Study to Assess The Efficacy and Safety of a PARP Inhibitor For The Treatment of BRCA-positive Advanced Breast Cancer View
NCT04182516 Study of NMS-03305293 in Pts with Selected AdvancedMetastatic Solid Tumors View
NCT02401347 Phase II Trial of Talazoparib in BRCA12 Wild-type HER2-negative Breast Cancer and Other Solid Tumors View
NCT02476968 To Assess the Efficacy and Safety of Olaparib Maintenance Monotherapy in the Treatment of Ovarian Cancer View
NCT01472783 Veliparib Monotherapy for Relapsed Ovarian Cancer With BRCA Mutation View
NCT01506609 Study Evaluating Efficacy And Tolerability Of Veliparib in Combination With Temozolomide TMZ or In Combination With Carboplatin and Paclitaxel Versus Placebo in Participants With Breast Cancer Gene BRCA1 and BRCA2 Mutation and Metastatic Breast Cancer View
NCT04960839 Prophylactic Irradiation to the Contralateral Breast for BCAs Patients View
NCT02950064 A Study to Determine the Safety of BTP-114 for Treatment in Patients With Advanced Solid Tumors With BRCA Mutations View
NCT05033756 Comprehensive Analysis of Predictors of the Treatment With Pembrolizumab and Olaparib in Patients With Unresectable or Metastatic HER2 Negative Breast Cancer and a Deleterious Germline Mutation or a Homologous Recombination Deficiency COMPRENDO View
NCT01689584 COsegregation of VARiants in Panel of Genes View
NCT00500383 Breast Cancer Risk Assessment Using Optical Breast Spectroscopy OBS View
NCT05097274 The GENPET Study - An Imaging Study of FCH-PET-CT in Men With Prostate Cancer and a DNA Repair Gene Mutation View
NCT01772979 Study With Trabectedin in BRCA1 and BRCA2 Mutation Carrier and BRCAness Phenotype Ovarian Cancer View
NCT03012321 AbirateronePrednisone Olaparib or AbirateronePrednisone Olaparib in Patients With Metastatic Castration-Resistant Prostate Cancer With DNA Repair Defects View
NCT03140670 Maintenance Rucaparib in BRCA1 BRCA2 or PALB2 Mutated Pancreatic Cancer That Has Not Progressed on Platinum-based Therapy View
NCT01992471 Multiplex Testing for Breast Cancer Susceptibility A Pilot Study of Subject Preferences for Information and Responses After Testing View
NCT03211611 Management of Women With BRCA12 Mutation View
NCT05305001 Germline Mutations Associated With Hereditary Pancreatic Cancer in Unselected Patients With Pancreatic Cancer in Mexico View
NCT05306002 Nutritional Intervention and DNA Damage of Patients With HBOC View
NCT02053805 Prostate Cancer Screening Among Men With High Risk Genetic Predisposition View
NCT05358639 Combination of Olaparib and Navitoclax in Women With HGSC and TNBC View
NCT00555503 Registry of Mastectomy for Breast Cancer Risk Reduction View
NCT02151747 Testing BRCA 12 Mutation Using Next Generation Sequencing View
NCT05409222 Study of Quality of Life Post Salpingo-oophorectomy in BRCA12 PALB2 Mutation Carriers BRCA-HRT View
NCT02225015 Cancer Prevention in Women With a BRCA Mutation View
NCT03471572 Study to Assess Prevalence of BRCA1 and BRCA2 Mutation Among Ovarian Primary Peritoneal and Fallopian Tube Cancer Patients in India View
NCT02302742 Triple Negative Breast Cancer and Germline Hereditary Breast and Ovarian Cancer Mutation Carrier Registry View
NCT02317120 BRCA1 and BRCA2 Mutation in Romanian Population a Study of Genotype - Phenotype Correlation at Diagnosis With Prospective Disease Outcome and Survival View
NCT02341118 Capturing BRCA12 Mutational Status in Women With High Grade Serous Ovarian Cancer and Impact on Clinical Outcome View
NCT02393794 Cisplatin Plus Romidepsin Nivolumab in Locally Recurrent or Metastatic Triple Negative Breast Cancer TNBC View
NCT02418624 Phase I of Carboplatin-Olaparib Followed by Olaparib Monotherapy in Advanced Cancer View
NCT02503436 C-PATROL - Non-interventional Study NIS to Collect Clinical and Patient Reported Outcome Data in an Olaparib Treated BRCAm PSR Ovarian Cancer Population View
NCT02557776 Written Genetic Counseling and Mutation Analysis of BRCA1 and BRCA2 to Patients With Breast Cancer View
NCT02571725 PARP-inhibition and CTLA-4 Blockade in BRCA-deficient Ovarian Cancer View
NCT02608346 Circulating Tumor DNA and Follow-up of BRCA1 Mutation Carriers CirCa 01 View
NCT05806515 Carboplatin Chemotherapy Before Surgery for People With High-Risk Prostate Cancer and an Inherited BRCA1 or BRCA2 Gene Mutation View
NCT02873975 A Study of LY2606368 Prexasertib in Patients With Solid Tumors With Replicative Stress or Homologous Repair Deficiency View
NCT02953457 Olaparib Durvalumab and Tremelimumab in Treating Patients With Recurrent or Refractory Ovarian Fallopian Tube or Primary Peritoneal Cancer With BRCA1 or BRCA2 Mutation View
NCT02978495 Neoadjuvant Carboplatin in Triple Negative Breast Cancer View
NCT03063710 Olaparib Expanded Access Program for BRCA Mutated Platinum Sensitive Relapsed High Grade Epithelial Ovarian Cancer Patients in Japan View
NCT03075735 Prospective Multicentre Cohort Study PROREPAIR-B mCRPC View
NCT03082976 Prevalence of BRCA1 and BRCA2 Mutations in Ovarian Cancer Patients in the Gulf Region View
NCT03205761 Analysis of Olaparib Response in Patients With BRCA1 andor 2 Promoter Methylation Diagnosed of Advanced Breast Cancer View
NCT03286842 To Study Clinical Effectiveness and Safety of Olaparib Monotherapy in Metastatic Breast Cancer Patients View
NCT03296826 Prospective Cohort Study of Germline Variant Carriers With BRCA1 or BRCA2 View
NCT04780945 Functional Analysis of BRCAness View
NCT06177171 Olaparib and ASTX727 in BRCA12- and Homologous Recombination Deficient HRD-Mutated Tumors View
NCT03495609 Use of Recombinant hCG to Prevent Breast Cancer in BRCA1 and BRCA2 Carriers View
NCT04823871 Early Detection of High Grade Ovarian Cancer Using Uterine Lavage EHUD Study and Duplex Sequencing View
NCT03685331 HOPE Olaparib Palbociclib and Fulvestrant in Patients With BRCA Mutation-associated HR HER2-metastatic Breast Cancer View
NCT06380751 Saruparib AZD5305 Plus Camizestrant Compared With CDK46 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive HER2-Negative IHC 0 1 2 ISH Non-amplified BRCA1 BRCA2 or PALB2m Advanced Breast Cancer View
NCT03786796 Study of Olaparib in Metastatic Renal Cell Carcinoma Patients With DNA Repair Gene Mutations View
NCT03918668 Study for the Knowledge of Risk Factors Associated With Breast Cancer in Women View
NCT06484725 Oncotype DX in BRCA-mutated Breast Cancer Patients Our Experience A Retrospective Observational Monocentric Study View
NCT04985721 A Trial of Pamiparib With Tislelizumab in Patients With Advanced Tumours With Homologous Recombination Repair Defects View
NCT04991480 A Study of ART4215 for the Treatment of Advanced or Metastatic Solid Tumors View
NCT00590109 Germline BRCA1 and BRCA2 Mutations in Jewish Women Affected by Breast Cancer View
NCT04093609 XIST Gene Deletion in Breast Cancer Therapy View
NCT04254133 Genetic Information to Inform Treatment and Screening for Prostate Cancer GIFTS Study View
NCT04261972 Cell-free DNA in Hereditary And High-Risk Malignancies View
NCT04265937 ScreenIng of Genetic Susceptibility Genes for Breast Cancer Patients in CHinese communiTies View
NCT04368442 Cohort Study of Patients With HER2-negative MBC and BRCA 12 Pathogenic Mutation View
NCT04428736 Evaluating Cascade Communication Methods View
NCT00700778 Recombinant Human Chorionic Gonadotropin in Preventing Breast Cancer in Premenopausal Women With BRCA1 Mutations View
NCT01866865 Adaptation to Living With a BRCA12 Mutation View
NCT04499534 BRCA12 Flu Vaccine View
NCT04598321 BrUOG 390 Neoadjuvant Treatment With Talazoparib View
NCT05958849 Advanced Pancreatic Cancer View
NCT05960773 DecitabineCedazuridine INQOVI an Oral DNA Demethylating Agent in Subjects With BAP1 Cancer Predisposition Syndrome and Subclinical Early-Stage Mesothelioma View
NCT00579488 Clinical Significance of Germline BRCA Mutations View
NCT04747717 Efficacy of Neoadjuvant Therapy With Cisplatin Plus Mitomycin C in BRCA1-Mutated Ovarian Cancer View
NCT04858334 APOLLO A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1 BRCA2 or PALB2 Mutation View
NCT04892693 Talazoparib in Advanced Breast Cancer Patients With Homologous Recombinant Deficiency View
NCT01874353 Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy View
NCT06111417 Use of an Ultra-rapid BRCA12 Status Screening Test in Theranostic Indication Performance and Interest for Patients and Practitioners View
NCT04983628 Molecular Profiling in Prostate Cancer View
NCT06115499 The PLATINUM Trial Optimizing Chemotherapy for the Second-Line Treatment of Metastatic BRCA12 or PALB2-Associated Metastatic Pancreatic Cancer View
NCT05062174 Breast Cancer BRCA1 Carriers a Pilot Study View
NCT05129605 Prostate Cancer Genetic Risk Evaluation and Screening Study View
NCT02365805 Randomized CT to Evaluate Efficacy of Neoadjuvant Chemotherapy Customized by Levels of BRCA1-HER2 Negative Breast Cancer View
NCT01907789 Prophylactic Salpingectomy With Delayed Oophorectomy View
NCT01905592 A Phase III Trial of Niraparib Versus Physicians Choice in HER2 Negative Germline BRCA Mutation-positive Breast Cancer Patients View
NCT05458570 Ethnic Predisposition Risk Factors Breast Cancer Presentation View
NCT05485766 Novel Neoadjuvant and Adjuvant Strategy for Germline BRCA 12 Mutated Triple Negative Breast Cancer View
NCT00321633 Carboplatin or Docetaxel in Treating Women With Metastatic Genetic Breast Cancer View
NCT05522491 Olaparib in the Treatment of BRCA12 Unmutated and BRCA1 Promoter Methylated Recurrent and Metastatic Triple-negative Breast Cancer View
NCT00673335 Letrozole in Preventing Breast Cancer in Postmenopausal Women With a BRCA1 or BRCA2 Mutation View
NCT05659914 Olaparib and Durvalumab MEDI4736 in Patients with Metastatic Pancreatic Cancer and DNA Damage Repair Genes Alterations View
NCT00753545 Assessment of Efficacy of AZD2281 in Platinum Sensitive Relapsed Serous Ovarian Cancer View
NCT00287898 Telephone-Based Genetic Counseling or Standard Genetic Counseling in Women at Risk of Carrying the BRCA1 or BRCA2 Mutation View
NCT06534424 Clinical Impact of Enhanced Risk Assessments in Women With a BRCA12 Mutation CARE Study View
NCT00080756 Deslorelin Combined With Low-Dose Add-Back Estradiol and Testosterone in Preventing Breast Cancer in Premenopausal Women Who Are at High Risk for This Disease View
NCT02039388 Lavage of the Uterine Cavity for the Diagnosis of Serous Tubal Intraepithelial Carcinoma View
NCT02940132 A Study of SC10914 in Patients With Advanced Solid Tumors View
NCT05835739 InheriteD brEast caNcer iTalian regIsTrY A Retrospective-prospective Observational Cohort Study to Evaluate Cancer Prevention Strategies in Women With a Deleterious Mutation in BRCA1-2 View
NCT01022333 The Potential for Oral Diindolylmethane DIM Supplementation to Increase the Production of the BRCA1 Protein in BRCA1 Mutation Carriers View
NCT06654050 Alrizomadlin APG-115 in Subjects With BAP1 Cancer Syndrome and Early-Stage Mesothelioma View
NCT03544983 Genetic Education in BRCA Families View
NCT06022029 A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas View
NCT01167842 Analysis of Tumors From Patients With Inherited Cancers Having Had Two Surgeries Primary Recurrent or 2 Separate Types of Cancer View
NCT01424709 Individualized Chemotherapy Based on BRCA1 and RRM1 mRNA for Advanced Non-small Cell Lung Cancer NSCLC View
NCT06478862 Promitil Treatment of Patients With Solid Tumors Associated With Deleterious Mutations Who Have Progressed After Therapy View
NCT06488378 Phase Ib Study of Axatilimab in Combination with Olaparib in BRCA12 and PALB2- Associated Metastatic HER2-negative Breast Cancer View
NCT00253539 Arzoxifene or Tamoxifen in Preventing Breast Cancer in Premenopausal Women at High Risk for Breast Cancer View
NCT01540565 Veliparib in Treating Patients With Persistent or Recurrent Epithelial Ovarian Fallopian Tube or Primary Peritoneal Cancer View
NCT00705549 Individualized Therapy Based of Tumoral mRNA Levels of ERCC1 RRM1 and BRCA1 in Advanced Non-Small-Cell Lung Cancer View
NCT02133703 Decision Support Following Genetic Testing for Breast-Ovarian Cancer Susceptibility View
NCT02139904 Vinorelbine in Mesothelioma View
NCT01562028 BELIEF Bevacizumab and ErLotinib In EGFR Mut NSCLC View
NCT03982446 Germline Mutations in Pancreatic Adenocarcinoma View
NCT02155777 Why do Oral Contraceptives Prevent Ovarian Cancer View
NCT00261456 The IMPACT Study - Identification of Men With a Genetic Predisposition to ProstAte Cancer View
NCT02593435 The Registration Program of BRCA12 Gene View
NCT02163694 A Phase 3 Randomized Placebo-controlled Trial of Carboplatin and Paclitaxel With or Without Veliparib ABT-888 in HER2-negative Metastatic or Locally Advanced Unresectable BRCA-associated Breast Cancer View
NCT04474834 GENetic Risk Estimation of Breast Cancer Prior to Decisions on Preventive Therapy Uptake Risk Reducing Surgery or Intensive Imaging Surveillance View
NCT05252390 NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors View
NCT05340413 Predicting Olaparib Sensitivity in Patients With Unresectable Locally AdvancedMetastatic HER2-negative Breast Cancer View
NCT02783664 Evaluating the Effects of Genetic Testing on Patients Stress Levels View
NCT02705846 Analysing Outcomes After Prostate Cancer Diagnosis and Treatment in Carriers of Rare Germline Mutations View
NCT04890613 Study of CX-5461 in Patients With Solid Tumours and BRCA12 PALB2 or Homologous Recombination Deficiency HRD Mutation View
NCT00001806 Methods in Education for Breast Cancer Genetics View
NCT01103128 Validation of a Mouse Model of Pancreatic Carcinogenesis View
NCT01434420 Triple Negative Breast Cancer Study of Molecular and Genetic Factors View
NCT02775461 Pancreas Registry and High Risk Registry View
NCT04038502 Carboplatin or Olaparib for BRcA Deficient Prostate Cancer View
NCT04150042 SHARON A Clinical Trial for Metastatic Cancer With a BRCA or PALB2 Mutation Using Chemotherapy and Patients Own Stem Cells View
NCT04171700 A Study to Evaluate Rucaparib in Participants With Solid Tumors and With Deleterious Mutations in HRR Genes View
NCT05333432 Evaluation of a Multimodal Strategy for Early Diagnosis of Men at High Genetic Risk of Prostate Cancer HRPCa-II View
NCT00098800 Fenretinide in Preventing Ovarian Cancer in Participants Who Are at High Risk for Developing Ovarian Cancer and Planning to Undergo Surgery to Remove the Ovaries View
NCT00005095 Specimen and Data Study for Ovarian Cancer Early Detection and Prevention View
NCT00084370 Celecoxib in Preventing Cancer in Patients at High Risk for Ovarian Epithelial Cancer Who Are Undergoing Prophylactic Oophorectomy View
NCT00304941 Insulin Resistance and Breast Cancer View
NCT00341159 Analysis of Data From the Womens Contraceptive and Reproductive Experiences CARE Study View
NCT00381927 Effect of Counseling on Psychological Stress Amongst Women Felt to be at High Risk for Breast Cancer Development View
NCT00580021 Clinical Outcomes in Hereditary Cancer View
NCT00580112 An Efficacy Study of Trabectedin in the Treatment of Participants With Specific Subtypes of Metastatic Breast Cancer View
NCT00582803 Adherence to Intensive Surveillance for Hereditary Breast Cancer View
NCT00642824 A Genetic Substudy Associated With the Avastin Bevacizumab Study MO19390 in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer View
NCT00664781 RucaparibCO-338Formally Called AG-014699 or PF-0136738 in Treating Patients With Locally Advanced or Metastatic Breast Cancer or Advanced Ovarian Cancer View
NCT00776958 Lynne Cohen Consortium Project Multi-Center DatabaseRegistry View
NCT00797238 DNA Repair Genes and Outcomes in Patients With Stage III NSCLC View
NCT02653105 Women at Risk of Breast Cancer and OLFM4 View
NCT02797964 A Phase 12 Trial of SRA737 in Subjects With Advanced Cancer View
NCT02797977 A Phase 12 Trial SRA737 in Combination With Gemcitabine and Cisplatin or Gemcitabine Alone in Advanced Cancer Subjects View
NCT02903004 Trial on Trabectedin ET-743 vs Clinicians Choice Chemotherapy in Recurrent Ovarian Primary Peritoneal or Fallopian Tube Cancers of BRCA Mutated or BRCAness Phenotype Patients View
NCT02957981 The Genetic Education for Men Trial Web-Based Education vs Standard Care View
NCT03044795 Response to PARP Inhibitor Predicted by the RAD51 Assay View
NCT03119285 Genes Contributing to Hereditary Ovarian Cancer in Women and BRCA12 Wildtype Families View
NCT03225170 Is it Feasible Self-Affirmation for Hereditary Breast and Ovarian Cancer Genetic Counseling View
NCT03343054 A Phase 1 Study Of Talazoparib PARP Inhibitor In Japanese Patients With Advanced Solid Tumors View
NCT03344965 Olaparib in Metastatic Breast Cancer View
NCT03503097 Genetic Testing for Men With Metastatic Prostate Cancer View
NCT03531840 Olaparib in People With Malignant Mesothelioma View
NCT03889171 Comparison to Psychological Medical and Emotional Influencing Communication and Achievement Factors to Oncogenetics Tests View
NCT03901469 A Study of ZEN003694 and Talazoparib in Patients With Triple Negative Breast Cancer View
NCT04012229 IMpact of Breast cAncer Gene Status on Survival in Adjuvant Breast Cancer IMBASSA View